18f-psma
Liver Metastasis Colon Cancer
Primo Biotechnology Co., LtdradiopharmaceuticalPhase 1Active
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 81/ 100
Competitive context
33 Active assets in the Liver Metastasis Colon Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin Fudan University | Phase 4 | BBB |
Fruquintinib Peking University | Phase 3 | BBB |
DEXAMETHASONE Fudan University | Phase 3 | BB |
Capecitabine Jun Huang | Phase 3 | BB |
Irinotecan Jun Huang | Phase 3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →